Emerging Detail
SCTX - Scribe Therapeutics Inc.
SNF Emerging Watchlist(TM) tracks newly public companies positioned around emerging economic themes. Inclusion reflects SNF research interest and ongoing monitoring; it is not a recommendation to buy, sell, or hold a security.
Emerging Score
80 / 100
Confidence
91%
Band
Strong Emerging Profile
Last Reviewed
Oct 23, 2026
Primary Theme
Biotechnology / Health Innovation
Exchange
Nasdaq
Current Thesis
Structural Theme Relevance
What Changed
Candidate to Candidate review completed.
Why It Matters
Structural Theme Relevance
What The Market Is Pricing In
Market Confirmation currently scores 50/100 within the Emerging Score framework.
What Could Change The Narrative
First-in-human execution for STX-1150 and proving clinical translation of the platform
SNF Lens
Signal
Structural Theme Relevance
Noise
Some evidence needs refresh context.
Confirmation
Market Confirmation 50/100
Risk
First-in-human execution for STX-1150 and proving clinical translation of the platform
Six-Family Scorecard
90
78
84
86
82
50
Key Risks
First-in-human execution for STX-1150 and proving clinical translation of the platform
Cash burn, safety and future financing requirements
Evidence Quality
Active Evidence
8
Sources
6
Stale Evidence
2
Freshness
Mixed freshness
Review / Score History
Oct 23, 2026Thesis unchanged - Candidate unchanged
Oct 4, 2026Thesis strengthened - Candidate unchanged
Oct 23, 2026Score 80 / Confidence 91 / Candidate
Oct 4, 2026Score 80 / Confidence 91 / Candidate
Sep 1, 2026Score 77 / Confidence 84 / Candidate
Sources